TargetMol

GW3965 hydrochloride

Product Code:
 
TAR-T6310
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6310-2mg2mg£99.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6310-5mg5mg£116.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6310-1mL1 mL * 10 mM (in DMSO)£134.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6310-10mg10mg£143.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6310-25mg25mg£230.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6310-50mg50mg£374.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6310-100mg100mg£522.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6310-500mg500mg£1,058.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
GW3965 HCl is an effective and specific LXR agonist for hLXRα/β (EC50: 190/30 nM).
CAS:
405911-17-3
Formula:
C33H32Cl2F3NO3
Molecular Weight:
618.52
Pathway:
Metabolism
Purity:
0.9975
SMILES:
Cl.OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1
Target:
Liver X Receptor

References

Guo D, et al. Cancer Discov. 2011, 1(5), 442-456. Joseph SB, et al. Proc Natl Acad Sci U S A. 2002, 99(11), 7604-7609. Collins JL, et al. J Med Chem. 2002, 45(10), 1963-1966. Scholz H, et al. Diabetologia. 2009, 52(7), 1352-1362. Leik CE, et al. Br J Pharmacol. 2007, 151(4), 450-456.